Who Paid My Doc
Ranjan Gupta
Hand Surgery Orange, CA Medical Doctor
NPI 1285714337 CMS profile 330683
Uci Medical Center, 101 The City Drive South, Orange, CA 92868
General payments
$209,794
Research payments
$0
Ownership & investment interest
$79,916
Through program year 2025, Ranjan Gupta of Orange, CA is reported in the CMS Open Payments database as having received $209,794 across 125 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $79,916 across 1 holding.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Hand Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $55,287 | 34 | |
| 2024 | General | $41,387 | 29 | |
| 2023 | General | $82,097 | 32 | |
| 2022 | General | $29,078 | 20 | |
| 2021 | General | $593 | 5 | |
| 2020 | General | $101 | 1 | |
| 2019 | General | $1,250 | 4 | |
| 2025 | Ownership | $79,916 | 1 |
Beside peers
- Ranjan Gupta
- Hand Surgery median
- Middle half of Hand Surgery
- National median
In program year 2025, general payments to Ranjan Gupta were reported at $55,287. Among 1,842 Hand Surgery profiles paid that year, the median was $270 and the middle half received between $102 and $1,118.
Show as a table
| Year | Ranjan Gupta | Hand Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,250 | $383 | $106–$1,905 | $163 |
| 2020 | $101 | $172 | $51–$1,268 | $114 |
| 2021 | $593 | $263 | $71–$1,591 | $132 |
| 2022 | $29,078 | $336 | $87–$1,938 | $149 |
| 2023 | $82,097 | $233 | $81–$1,114 | $160 |
| 2024 | $41,387 | $258 | $88–$1,203 | $164 |
| 2025 | $55,287 | $270 | $102–$1,118 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 63 billing codesPaid by Medicare
$52,428
Medicare patients
178
Services billed
419
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 39% | |
| Ischemic heart disease | 29% | |
| Depression | 28% | |
| Osteoporosis | 28% | |
| Chronic kidney disease | 26% | |
| Atrial fibrillation | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
125 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hand Surgery in California
Related records
Hand Surgery in California
Practitioners in the same specialty and state, ranked by reported value.
All Hand Surgery
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.